Datopotamab Deruxtecan (Datroway)
Indication: Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Population PK simulator for datopotamab deruxtecan (Dato-DXd, Datroway) — TROP2-directed ADC for NSCLC and breast cancer. Simulates intact ADC (2-CMT, parallel linear + Michaelis-Menten clearance) and free DXd payload with albumin and body weight covariates. Based on Hong et al. CPT:PSP 2025. Compare payload exposure to T-DXd.
Drug Overview
Clinical Context
- Molecular Target
- TROP2
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology
- Indication
- Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Datopotamab Deruxtecan (Datroway) allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload) model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Datopotamab Deruxtecan (Datroway) PK simulator?
This is a free, interactive pharmacokinetic simulator for Datopotamab Deruxtecan (Datroway) used in Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Datopotamab Deruxtecan (Datroway) belong to?
Datopotamab Deruxtecan (Datroway) is classified as a Antibody-Drug Conjugate (ADC) that targets TROP2. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of Datopotamab Deruxtecan (Datroway). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload) model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
Patritumab Deruxtecan (HER3-DXd) PopPK
EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
Ready to Simulate?
Launch the Datopotamab Deruxtecan (Datroway) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community